Partnership to Distribute Updated Phenyx Platform in France
News Sep 21, 2005
Geneva Bioinformatics (GeneBio) S.A. has announced a partnership agreement with Proteomic Solutions. Under the terms of the agreement, Proteomic Solutions will distribute Phenyx throughout France.
GeneBio’s Phenyx is a software platform for the identification and characterization of proteins and peptides from mass spectrometry data.
Developed by GeneBio in collaboration with the Swiss Institute of Bioinformatics (SIB) and incorporating the true probabilistic and flexible scoring system OLAV, Phenyx is designed to meet the concurrent demands of high-throughput MS data analysis and dynamic high quality results assessment.
GeneBio has recently communicated major updates to Phenyx, including the release of a dynamic Web-based client interface to implement the platform.
“We are delighted to once again be working with Proteomic Solutions in order to strengthen our presence in the key French mass spectrometry area,” said Nasri Nahas, CEO of GeneBio.
“Proteomic Solutions is a well known player in the Proteomics field and we look forward to capitalizing on their experience and expertise in order to expand the reach of Phenyx in the French market.”
“We are excited to again be working with GeneBio and believe that the Phenyx platform will have great traction in the market,” said Philippe Dutriat, CEO of Proteomic Solutions.
“We believe Phenyx has both the fundamental technology and the underlying feature set necessary to make a major impact on the French market and are pleased to have the chance to prove it. We look forward to a prosperous relationship with GeneBio.”
GeneBio will be demonstrating the latest release of Phenyx, including the Phenyx Web Interface, at the 1st Symposium of Analytical Chemistry and Biology in Montpellier, France, from September 26 – 29.
Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord, Mature neurons, however, are unable to regenerate their axons to facilitate this process. New research in mice shows one potential route to overcome this limitation may be by targeting liver kinase B1 (LKB1) protein.
Pre-Filled Syringes & Injectable Drug Devices Europe
Jan 16 - Jan 17, 2019
3rd International Conference and Exhibition on Nanomedicine and Drug Delivery
Mar 13 - Mar 14, 2019
International Conference on Cell and Structural biology
Jul 15 - Jul 16, 2019